Safoora Fatima1, Anne Holbrook2, Sam Schulman3, Steve Park4, Sue Troyan4, Greg Curnew3. 1. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. 2. Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada; Division of Clinical Pharmacology and Toxicology, McMaster University, Hamilton, ON, Canada; Clinical Pharmacology, St Joseph's Healthcare Hamilton, Canada. Electronic address: holbrook@mcmaster.ca. 3. Department of Medicine, McMaster University, Hamilton, ON, Canada. 4. Clinical Pharmacology, St Joseph's Healthcare Hamilton, Canada.
Abstract
BACKGROUND: Multiple antithrombotic agents are available for stroke prevention in atrial fibrillation (AF). A decision aid can assist patients in making informed decisions that best serves their needs. OBJECTIVE: To validate a decision aid to assist patients in choosing between antithrombotic agents (antiplatelets, warfarin, direct-acting oral anticoagulants (DOACs)) for AF. METHODS: Patients (60years or older) were recruited for this prospective study. The decision aid presented descriptions related to AF, then charts portraying important outcomes for comparisons between 1) no treatment, aspirin and anticoagulants, 2) warfarin versus DOACs, and 3) DOAC versus DOAC. The primary outcome was confidence in making treatment decisions. The secondary outcomes included change in knowledge scores, ratings of clarity, helpfulness and comprehensiveness. RESULTS: Eighty-one patients (mean age 75.2 [SD 7.5], 77% taking an anticoagulant) participated. After using the decision aid, mean decisional conflict score was low at 7.2 [SD 10.8] on a scale from 1 to 100. Mean knowledge score (total possible 10) improved from 7.4 [SD 1.7] to 9.3 [SD 1.0] (p<0.001). The mean helpfulness score in making a treatment choice was high at 6.2 [SD 0.9] on a scale from 1 to 7. No participant found the decision aid difficult to understand. Information in the decision aid was rated as good or excellent in terms of clarity and comprehensiveness. CONCLUSIONS: Our decision aid addresses a key medication safety gap - assisting patients to participate in shared decisions about anticoagulation. Future research is required to evaluate how decision aids influence actual choices and clinical outcomes.
BACKGROUND: Multiple antithrombotic agents are available for stroke prevention in atrial fibrillation (AF). A decision aid can assist patients in making informed decisions that best serves their needs. OBJECTIVE: To validate a decision aid to assist patients in choosing between antithrombotic agents (antiplatelets, warfarin, direct-acting oral anticoagulants (DOACs)) for AF. METHODS:Patients (60years or older) were recruited for this prospective study. The decision aid presented descriptions related to AF, then charts portraying important outcomes for comparisons between 1) no treatment, aspirin and anticoagulants, 2) warfarin versus DOACs, and 3) DOAC versus DOAC. The primary outcome was confidence in making treatment decisions. The secondary outcomes included change in knowledge scores, ratings of clarity, helpfulness and comprehensiveness. RESULTS: Eighty-one patients (mean age 75.2 [SD 7.5], 77% taking an anticoagulant) participated. After using the decision aid, mean decisional conflict score was low at 7.2 [SD 10.8] on a scale from 1 to 100. Mean knowledge score (total possible 10) improved from 7.4 [SD 1.7] to 9.3 [SD 1.0] (p<0.001). The mean helpfulness score in making a treatment choice was high at 6.2 [SD 0.9] on a scale from 1 to 7. No participant found the decision aid difficult to understand. Information in the decision aid was rated as good or excellent in terms of clarity and comprehensiveness. CONCLUSIONS: Our decision aid addresses a key medication safety gap - assisting patients to participate in shared decisions about anticoagulation. Future research is required to evaluate how decision aids influence actual choices and clinical outcomes.
Authors: Marleen Kunneman; Megan E Branda; Ian G Hargraves; Angela L Sivly; Alexander T Lee; Haeshik Gorr; Bruce Burnett; Takeki Suzuki; Elizabeth A Jackson; Erik Hess; Mark Linzer; Sarah R Brand-McCarthy; Juan P Brito; Peter A Noseworthy; Victor M Montori Journal: JAMA Intern Med Date: 2020-07-20 Impact factor: 21.873
Authors: Mina K Chung; Angela Fagerlin; Paul J Wang; Tinuola B Ajayi; Larry A Allen; Tina Baykaner; Emelia J Benjamin; Megan Branda; Kerri L Cavanaugh; Lin Y Chen; George H Crossley; Rebecca K Delaney; Lee L Eckhardt; Kathleen L Grady; Ian G Hargraves; Mellanie True Hills; Matthew M Kalscheur; Daniel B Kramer; Marleen Kunneman; Rachel Lampert; Aisha T Langford; Krystina B Lewis; Ying Lu; John M Mandrola; Kathryn Martinez; Daniel D Matlock; Sarah R McCarthy; Victor M Montori; Peter A Noseworthy; Kate M Orland; Elissa Ozanne; Rod Passman; Krishna Pundi; Dan M Roden; Elizabeth V Saarel; Monika M Schmidt; Samuel F Sears; Dawn Stacey; Randall S Stafford; Benjamin A Steinberg; Sojin Youn Wass; Jennifer M Wright Journal: Circ Arrhythm Electrophysiol Date: 2021-12-06
Authors: Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori Journal: Mayo Clin Proc Date: 2019-01-11 Impact factor: 7.616
Authors: Victor D Torres Roldan; Sarah R Brand-McCarthy; Oscar J Ponce; Tereza Belluzzo; Meritxell Urtecho; Nataly R Espinoza Suarez; Freddy J K Toloza; Anjali D Thota; Paige W Organick; Francisco Barrera; Carolina Liu-Sanchez; Soumya Jaladi; Larry Prokop; Elissa M Ozanne; Angela Fagerlin; Ian G Hargraves; Peter A Noseworthy; Victor M Montori; Juan P Brito Journal: Med Decis Making Date: 2021-04-24 Impact factor: 2.583
Authors: Marleen Kunneman; Megan E Branda; Ian G Hargraves; Angela L Sivly; Alexander T Lee; Haeshik Gorr; Bruce Burnett; Takeki Suzuki; Elizabeth A Jackson; Erik Hess; Mark Linzer; Sarah R Brand-McCarthy; Juan P Brito; Peter A Noseworthy; Victor M Montori Journal: JAMA Intern Med Date: 2020-09-01 Impact factor: 21.873